MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Sponsored by Endotronix, Inc.
Remote PA Pressure Monitoring and Proactive Management of a Heart Failure Patient
Use of the Cordella® HF System for PA pressure-guided heart failure management.
By Gillian Grafton, DO, and Jennifer A. Cowger, MD, MS, FACC
Procyrion’s Aortix Pump Therapy Evaluated in Pilot Study to Treat Cardiorenal Syndrome
March 21, 2023—Procyrion, Inc. announced findings from a pilot study of its Aortix percutaneous mechanical circulatory support device that demonstrated rapid decongestion in patients admitted to the hospital with acute decompensated heart failure and worsening renal function, which is known as cardiorenal syndrome (CRS).
DRAIN-HF Pivotal IDE Trial of Procyrion’s Aortix pMCS Device Begins Enrollment
November 30, 2023—Procyrion, Inc. announced the enrollment of the first patients in the company’s DRAIN-HF pivotal trial of the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heart failure (ADHF) who are unresponsive to standard medical therapy.
Procyrion’s Aortix Percutaneous Mechanical Circulatory Support Device Evaluated in Pilot CRS Study
May 25, 2021—Procyrion, Inc. announced the successful treatment of the first patients in the company’s pilot trial to evaluate the performance of its Aortix percutaneous mechanical circulatory support device in patients with cardiorenal syndrome (CRS).
Procyrion’s Aortix Pump Evaluated in FIH Study to Prevent AKI in Cardiac Surgery Patients
February 22, 2023—Procyrion, Inc. announced the successful treatment of the first patients in the A PRIORI pilot trial evaluating the performance of the company’s Aortix percutaneous mechanical circulatory support (pMCS) device in preventing acute kidney injury (AKI) during cardiac surgery.
Abbott Initiates TEAM-HF Clinical Trial Using CardioMEMS HF System
November 11, 2024—Abbott recently announced plans to conduct the TEAM-HF clinical trial, which is designed to improve outcomes in patients with worsening heart failure (HF) who could benefit from advanced therapy options.
